Characterization of the Synergistic Inhibition of <i>I</i><sub>K(erg)</sub> and <i>I</i><sub>K(DR)</sub> by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor

Ribociclib (RIB, LE011, Kisqali<sup>®</sup>), an orally administered inhibitor of cyclin-dependent kinase-4/6 (CDK-4/6) complex, is clinically effective for the treatment of several malignancies, including advanced breast cancer. However, information regarding the effects of RIB on membr...

Full description

Bibliographic Details
Main Authors: Pin-Yen Liu, Wei-Ting Chang, Sheng-Nan Wu
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/21/8078

Similar Items